NASDAQ : CVKD
Cadrenal Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 0.985 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.51M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Selling, General & Admin | 8.82M | 9.35M | 6.75M | 3.55M | 2.52M |
| Research & Development | 2.83M | 4.10M | 4.21M | 4.08M | 428.57K |
| Operating Expenses | 11.65M | 13.46M | 10.96M | 7.63M | 2.95M |
| Operating Income | -11.65M | -13.46M | -10.96M | -7.63M | -2.95M |
| Interest Expense | -17.10K | -116.86K | |||
| Interest & Investment Income | 109.89K | 223.81K | 309.25K | 249.09K | 23.00 |
| Other Non Operating Income (Expenses) | -216.09K | -4.26M | |||
| EBT Excluding Unusual Items | -11.54M | -13.24M | -10.65M | -7.62M | -7.32M |
| Other Unusual Items | -740.14K | ||||
| Pretax Income | -11.54M | -13.24M | -10.65M | -8.36M | -7.32M |
| Net Income | -11.54M | -13.24M | -10.65M | -8.36M | -7.32M |
| Net Income to Common | -11.54M | -13.24M | -10.65M | -8.36M | -7.32M |
| Shares Outstanding (Basic) | 2.37M | 1.99M | 1.22M | 899.47K | 526.03K |
| Shares Outstanding (Diluted) | 2.37M | 1.99M | 1.22M | 899.47K | 526.03K |
| EPS (Basic) | -4.86 | -6.64 | -8.73 | -9.29 | -13.92 |
| EPS (Diluted) | -4.86 | -6.64 | -8.73 | -9.29 | -13.92 |
| Free Cash Flow | -10.16M | -12.61M | -7.36M | -3.53M | -1.32M |
| Free Cash Flow Per Share | -4.28 | -6.32 | -6.04 | -3.93 | -2.50 |
| EBITDA | -11.65M | -13.45M | -10.96M | -7.63M | -2.95M |
| D&A For EBITDA | 2.02K | 6.87K | 1.88K | 1.98K | 1.38K |
| EBIT | -11.65M | -13.46M | -10.96M | -7.63M | -2.95M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.39M | 4.01M | 10.02M | 8.40M | 32.59K |
| Cash & Short-Term Investments | 2.39M | 4.01M | 10.02M | 8.40M | 32.59K |
| Other Receivables | 2.69M | 5.10K | 38.15K | 37.25K | |
| Receivables | 2.69M | 5.10K | 38.15K | 37.25K | |
| Prepaid Expenses | 410.11K | 200.14K | 42.26K | 52.42K | 22.71K |
| Other Current Assets | 95.67K | 106.34K | 14.45K | 672.29K | |
| Total Current Assets | 5.58M | 4.32M | 10.11M | 8.49M | 727.60K |
| Property, Plant & Equipment | 2.67K | 5.17K | 6.94K | 23.29K | 44.59K |
| Other Long-Term Assets | 2.17K | 2.17K | 3.79K | 3.79K | 5.99K |
| Total Assets | 5.59M | 4.33M | 10.12M | 8.52M | 778.17K |
| Accounts Payable | 871.91K | 650.66K | 1.50M | 167.32K | 404.90K |
| Accrued Expenses | 625.34K | 937.32K | 1.18M | 638.21K | 863.56K |
| Short-Term Debt | 43.73K | ||||
| Current Portion of Leases | 21.35K | 22.29K | |||
| Total Current Liabilities | 1.50M | 1.59M | 2.68M | 826.88K | 1.33M |
| Long-Term Debt | 553.34K | ||||
| Long-Term Leases | 21.35K | ||||
| Other Long-Term Liabilities | 4.42M | ||||
| Total Liabilities | 1.50M | 1.59M | 2.68M | 826.88K | 6.33M |
| Common Stock | 3.10K | 2.34K | 1.78K | 868.00 | 8.19K |
| Additional Paid-In Capital | 48.87M | 41.70M | 33.16M | 22.76M | 1.15M |
| Retained Earnings | -44.78M | -38.96M | -25.72M | -15.07M | -6.71M |
| Shareholders' Equity | 4.09M | 2.74M | 7.44M | 7.69M | -5.55M |
| Total Liabilities & Equity | 5.59M | 4.33M | 10.12M | 8.52M | 778.17K |
| Total Debt | 21.35K | 640.71K | |||
| Net Cash (Debt) | 2.39M | 4.01M | 10.02M | 8.38M | -608.12K |
| Net Cash Per Share | 1.01 | 2.01 | 8.21 | 9.32 | -1.16 |
| Filing Date Shares Outstanding | 3.57M | 2.51M | 1.88M | 1.07M | 775.64K |
| Total Common Shares Outstanding | 3.10M | 2.34M | 1.78M | 868.18K | 546.26K |
| Working Capital | 4.09M | 2.73M | 7.43M | 7.67M | -606.88K |
| Book Value Per Share | 1.32 | 1.17 | 4.17 | 8.86 | -10.16 |
| Tangible Book Value | 4.09M | 2.74M | 7.44M | 7.69M | -5.55M |
| Tangible Book Value Per Share | 1.32 | 1.17 | 4.17 | 8.86 | -10.16 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -11.54M | -13.24M | -10.65M | -8.36M | -7.32M |
| Depreciation & Amortization | 2.02K | 6.87K | 1.88K | 1.98K | 1.38K |
| Other Amortization | 13.57K | 73.00K | |||
| Stock-Based Compensation | 1.72M | 1.94M | 1.42M | 710.38K | 1.01M |
| Other Operating Activities | -352.00 | 3.96M | 4.26M | ||
| Change in Accounts Payable | -23.70K | -851.80K | 1.34M | -237.58K | 441.71K |
| Change in Other Net Operating Assets | -319.95K | -459.27K | 538.10K | 381.89K | 221.28K |
| Operating Cash Flow | -10.16M | -12.60M | -7.36M | -3.53M | -1.31M |
| Capital Expenditures | -1.85K | -5.10K | -6.54K | -3.25K | -2.49K |
| Investing Cash Flow | -412.00 | -5.10K | -6.54K | -3.25K | -2.49K |
| Total Debt Issued | 1.34M | ||||
| Short-Term Debt Repaid | -250.00K | ||||
| Total Debt Repaid | -250.00K | ||||
| Net Debt Issued (Repaid) | -250.00K | 1.34M | |||
| Issuance of Common Stock | 5.24M | 7.16M | 5.14M | 12.15M | 8.67K |
| Other Financing Activities | 1.74M | -563.10K | 3.84M | ||
| Financing Cash Flow | 6.98M | 6.60M | 8.98M | 11.90M | 1.35M |
| Net Cash Flow | -3.18M | -6.01M | 1.62M | 8.37M | 35.55K |
| Free Cash Flow | -10.16M | -12.61M | -7.36M | -3.53M | -1.32M |
| Free Cash Flow Per Share | -4.28 | -6.32 | -6.04 | -3.93 | -2.50 |
| Levered Free Cash Flow | -8.54M | -7.78M | -3.56M | -3.92M | |
| Unlevered Free Cash Flow | -8.54M | -7.78M | -3.56M | -3.92M | |
| Change in Working Capital | -343.65K | -1.31M | 1.87M | 144.31K | 662.98K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 3.73M | 15.85M | 25.83M | 9.64M | |
| Enterprise Value | 1.34M | 11.99M | 21.47M | 553.30K | |
| Last Close Price | 0.98 | 6.78 | 14.49 | 11.10 | |
| PB Ratio | 0.75 | 5.79 | 3.47 | 1.25 | |
| P/TBV Ratio | 0.86 | 5.79 | 3.47 | 1.25 | |
| Debt / Equity Ratio | 0.00 | -0.12 | |||
| Net Debt / Equity Ratio | -0.58 | -1.46 | -1.35 | -1.09 | -0.11 |
| Net Debt / EBITDA Ratio | 0.20 | 0.30 | 0.91 | 1.10 | -0.21 |
| Net Debt / FCF Ratio | 0.23 | 0.32 | 1.36 | 2.37 | -0.46 |
| Quick Ratio | 3.39 | 2.53 | 3.75 | 10.21 | 0.02 |
| Current Ratio | 3.73 | 2.72 | 3.77 | 10.27 | 0.55 |
| Return on Equity (ROE) | -275.16% | -260.11% | -140.78% | -780.59% | |
| Return on Assets (ROA) | -125.93% | -116.44% | -73.49% | -102.62% | |
| Return on Capital Employed (ROCE) | -284.80% | -491.50% | -147.30% | -99.20% | 529.80% |
| Earnings Yield | -465.50% | -83.50% | -41.24% | -86.73% | |
| FCF Yield | -289.25% | -79.53% | -28.51% | -36.67% | |
| Buyback Yield / Dilution | -44.92% | -63.48% | -35.59% | -70.99% |